Stifel Financial Corp (NYSE:SF). has announced a revision to its executive compensation structure, according to a recent SEC filing. On Monday, the Compensation Committee of the Board of Directors ...

Twilio (NYSE:TWLO – Get Free Report) had its price objective upped by stock analysts at Stifel Nicolaus from $110. ... and sold shares of TWLO. True Wealth Design LLC grew its position in shares ...

In a report released yesterday, Shlomo Rosenbaum from Stifel Nicolaus maintained a Hold rating on Cintas (CTAS – Research Report). The company’s shares closed yesterday at $197.39. According ...

In a report released yesterday, Matthew Smith, CFA from Stifel Nicolaus maintained a Hold rating on TreeHouse Foods (THS – Research Report), with a price target of $35.00. The company’s shares ...

According to the Stifel report, the transport and logistics (T&L) sector is entering 2025 with lower earnings expectations and an investor base that has adjusted to a "new normal." However, the ...

Thursday, January 23, 2025, marks the release of a new report by Stifel analysts on the US transport sector. The report outlines a cautious perspective on the industry's future, noting that while 2024 ...

Thursday, January 23, 2025, marks the release of a new report by Stifel analysts on the US transport sector. The report outlines a cautious perspective on the industry's future, noting that while ...

Stifel has initiated coverage of Cytokinetics (NASDAQ:CYTK) with a buy rating, citing its drug aficamten. The bank noted the stock was "out of favor" in the wake of a "controversial" deal with ...

There never has been a better time than now to manage the wealth of the rich, as the parabolic rally in equities in the post-pandemic era swelled the ranks and bank balances of the extreme rich in ...

The companies offer a range of established services, such as wealth management, along with emerging solutions in high demand, such as co-living spaces and artificial intelligence (AI). The list ...

LVMH (LVMHF) has reclaimed its spot as the biggest company in Europe, overtaking Novo Nordisk (NYSE:NVO) after a significant drop in the drugmaker's shares. The cause? Concerns that the US ...